Applied Nutrition FY26 results: revenue jumps 50.9% but cash conversion falls
Applied Nutrition delivered rapid FY26 growth and maintained its FY27 outlook, but margins, working capital and cash conversion need watching.
This article covers information on Applied Nutrition PLC.
LON:APNApplied Nutrition has delivered another year of rapid growth, with revenue rising by more than half and adjusted EBITDA reaching management's upgraded expectations.
The sports nutrition and wellness group released its unaudited preliminary results on 16 November 2026. These cover the financial year ended 31 July 2026, rather than the current FY27 period.
The headline performance is impressive. However, investors also need to consider lower margins, heavier working capital requirements and a sharp reduction in free cash flow conversion.
Applied Nutrition's key FY26 figures
| Financial measure | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue | £161.6 million | £107.1 million | 50.9% |
| Gross profit | £71.3 million | £49.3 million | 44.6% |
| Adjusted EBITDA | £43.3 million | £30.9 million | 40.1% |
| Adjusted profit before tax | £42.0 million | £30.2 million | 39.1% |
| Adjusted EPS | 12.5p | 9.1p | 37.4% |
| Statutory profit before tax | £41.0 million | £28.5 million | 43.9% |
| Free cash flow | £10.6 million | £16.5 million | -35.8% |
| Free cash flow conversion | 33.5% | 72.4% | - |
Adjusted EBITDA means earnings before interest, tax, depreciation and amortisation, excluding exceptional and significant non-underlying items. It is a company-defined measure intended to show underlying operating performance.
The difference between adjusted and statutory results was relatively modest. Applied Nutrition reported £1.0 million of acquisition-related and post-acquisition costs, compared with £1.7 million of IPO costs in FY25.
Growth was broad rather than acquisition-led
Group revenue increased by £54.5 million to £161.6 million. The Nutrablend acquisition contributed only £1.6 million during the year, meaning organic revenue growth was 49.4%.
That is an important detail. FY26 growth was overwhelmingly generated by the existing business rather than purchased through acquisitions.
All three reported geographic regions expanded by at least 34%:
| Geography | FY26 revenue | Growth |
|---|---|---|
| UK | £70.3 million | 45.2% |
| Europe | £20.9 million | 34.0% |
| Rest of World | £70.4 million | 63.3% |
UK grocery sales rose by 180%, while high-street health revenue increased by more than 65%. Latin American sales grew by over 190%, and Asia-Pacific revenue rose by almost 60%.
The customer performance was similarly broad. Of Applied Nutrition's top 50 business-to-business customers, 48 delivered growth and 45 achieved double-digit or triple-digit increases.
This builds on the expansion reported in Applied Nutrition's H1 FY26 results, with management saying performance accelerated through the second half.
Product innovation is widening the audience
Applied Nutrition continued expanding beyond products aimed solely at traditional gym users.
The company launched new products and formats across protein, hydration, collagen, creatine and general wellness. It also introduced a range aimed at consumers using GLP-1 weight-loss treatments and agreed an out-licensing deal with Morrisons for high-protein foods.
Critical Whey sales increased by 142% following a reformulation and relaunch. Direct-to-consumer revenue, although still described as a relatively small part of the business, grew by 51%.
Brand collaborations are another part of the strategy. The SLUSH PUPPiE range performed strongly, while products using the SOUR PATCH KIDS and SWEDISH FISH brands are intended to broaden the group's North American appeal.
Following the year end, SOUR PATCH KIDS products were launched in 2,200 Walmart stores and 1,300 GNC corporate stores. Applied Nutrition described the early sales data as encouraging but did not disclose figures.
US acquisition adds capacity and execution risk
Applied Nutrition completed its first acquisition in June 2026, buying the trade and most of the assets of US manufacturer Nutrablend for approximately £12 million in cash.
The Buffalo operation gives the group local manufacturing and warehousing capacity capable of supporting around $300 million of annual revenue. Management expects it to shorten lead times and improve service for North American customers.
In the UK, construction has also started on a production extension, global distribution facility and head office. Once completed, the UK facilities are expected to support approximately £300 million of annual revenue.
This provides substantial potential headroom against FY26 revenue of £161.6 million. Capacity alone does not guarantee demand, but the investment should reduce the risk of infrastructure becoming an immediate constraint if growth continues.
The US operation also introduces integration risk. It required recapitalisation after acquisition and is expected to operate at lower margins than the existing business, partly because it generates more white-label sales.
Why cash conversion fell
Free cash flow declined by 35.8% to £10.6 million, despite the strong increase in profit. Conversion of adjusted profit after tax into free cash flow dropped from 72.4% to 33.5%.
The main pressure came from working capital, meaning cash tied up in day-to-day trading assets and liabilities.
Inventories increased from £22.8 million to £44.5 million, while trade and other receivables rose from £27.4 million to £42.8 million. Total working capital usage reached £55.6 million, up from £33.1 million.
Management attributed this to business growth, additional stock, the acquisition and preparations for anticipated customer demand. It expects working capital requirements to increase further in the short term as the US operation is recapitalised and higher whey protein prices feed into inventory costs.
Applied Nutrition still ended FY26 with £15.9 million of net cash, excluding lease liabilities, after funding the acquisition. It also had an undrawn £30 million revolving credit facility.
There was no FY26 dividend, compared with £14.7 million paid in FY25. The company does not anticipate declaring another dividend before FY28, as cash is being retained for capacity, efficiency and possible acquisitions.
Margins are the main financial pressure point
Gross margin declined from 46.0% to 44.1%, a reduction of 1.9 percentage points. Management cited higher staff costs and temporary off-site storage and logistics requirements.
My calculation: FY26's adjusted EBITDA margin was approximately 26.8%, using adjusted EBITDA of £43.3 million divided by revenue of £161.6 million. The equivalent FY25 margin was approximately 28.9%, based on £30.9 million divided by £107.1 million.
That represents a decline of roughly 2.1 percentage points despite the sharp increase in absolute profit.
The company expects the FY27 EBITDA margin to fall slightly again because of lower-margin US revenue, increased whey protein costs and a greater proportion of whey-based product sales. Customer price increases have partly mitigated the raw-material pressure.
What Applied Nutrition expects for FY27
The group maintained its previously announced FY27 expectations of approximately:
- £205 million of revenue
- £49 million of adjusted EBITDA
My calculation: compared with FY26, those figures would represent revenue growth of approximately 26.9% and adjusted EBITDA growth of approximately 13.2%.
They also imply an adjusted EBITDA margin of approximately 23.9%, calculated by dividing £49 million by £205 million. This is an interpretation of the supplied figures, not separate company guidance.
Management said trading remained very strong during the first quarter, with further market share gains across key channels. However, because FY27 remains at an early stage, the board has not increased expectations.
What investors should watch next
The strongest part of this update is the quality and breadth of the revenue growth. Organic expansion was 49.4%, every geographic division grew strongly and the group retained net cash after completing its first acquisition.
The trade-off is that profit growth is not fully reaching cash flow. Inventory requirements are increasing, gross and EBITDA margins have declined, and management expects further near-term working capital investment.
For Applied Nutrition PLC, the next test is therefore not simply whether it can keep selling more products. Investors should watch whether the US expansion, new capacity and product launches can deliver growth without placing prolonged pressure on margins and cash generation.
Related
Keep reading
Investing
Could Japan’s Monetary Policy Trigger a U.S. Market Crash?
Japan’s monetary policy can influence markets far beyond Tokyo. Here is how yen-funded trades, foreign bond portfolios and funding stress could amplify volatility, and what long-term investors should monitor.
JoshuaNovember 16, 2026
Investing
Individual Stocks or Index Funds: What Matters Over the Long Term?
Holding one successful company for decades can produce an exceptional result. It can also leave your wealth dependent on a single business. Here is a practical framework for comparing individual stocks with diversified指数
JoshuaNovember 16, 2026
Investing
How higher Treasury yields expose balance-sheet risk
Higher government bond yields do not affect every company equally. The important questions concern debt maturities, credit spreads, cash generation and the obligations that sit beyond headline borrowings.
JoshuaNovember 16, 2026
Tagged
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.